Literature DB >> 22698401

LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.

Wenjin Liu1, Kimberly B Monahan, Adam D Pfefferle, Takeshi Shimamura, Jessica Sorrentino, Keefe T Chan, David W Roadcap, David W Ollila, Nancy E Thomas, Diego H Castrillon, C Ryan Miller, Charles M Perou, Kwok-Kin Wong, James E Bear, Norman E Sharpless.   

Abstract

Germline mutations in LKB1 (STK11) are associated with the Peutz-Jeghers syndrome (PJS), which includes aberrant mucocutaneous pigmentation, and somatic LKB1 mutations occur in 10% of cutaneous melanoma. By somatically inactivating Lkb1 with K-Ras activation (±p53 loss) in murine melanocytes, we observed variably pigmented and highly metastatic melanoma with 100% penetrance. LKB1 deficiency resulted in increased phosphorylation of the SRC family kinase (SFK) YES, increased expression of WNT target genes, and expansion of a CD24(+) cell population, which showed increased metastatic behavior in vitro and in vivo relative to isogenic CD24(-) cells. These results suggest that LKB1 inactivation in the context of RAS activation facilitates metastasis by inducing an SFK-dependent expansion of a prometastatic, CD24(+) tumor subpopulation.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22698401      PMCID: PMC3660964          DOI: 10.1016/j.ccr.2012.03.048

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  53 in total

1.  The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death.

Authors:  P Karuman; O Gozani; R D Odze; X C Zhou; H Zhu; R Shaw; T P Brien; C D Bozzuto; D Ooi; L C Cantley; J Yuan
Journal:  Mol Cell       Date:  2001-06       Impact factor: 17.970

2.  p16(Ink4a) in melanocyte senescence and differentiation.

Authors:  Elena V Sviderskaya; Simon P Hill; Tracy J Evans-Whipp; Lynda Chin; Seth J Orlow; David J Easty; Sok Ching Cheong; David Beach; Ronald A DePinho; Dorothy C Bennett
Journal:  J Natl Cancer Inst       Date:  2002-03-20       Impact factor: 13.506

3.  Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas.

Authors:  A Rowan; V Bataille; R MacKie; E Healy; D Bicknell; W Bodmer; I Tomlinson
Journal:  J Invest Dermatol       Date:  1999-04       Impact factor: 8.551

4.  AMP-activated protein kinase induces a p53-dependent metabolic checkpoint.

Authors:  Russell G Jones; David R Plas; Sara Kubek; Monica Buzzai; James Mu; Yang Xu; Morris J Birnbaum; Craig B Thompson
Journal:  Mol Cell       Date:  2005-04-29       Impact factor: 17.970

5.  Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer.

Authors:  J Jonkers; R Meuwissen; H van der Gulden; H Peterse; M van der Valk; A Berns
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

6.  CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells.

Authors:  M-Q Gao; Y-P Choi; S Kang; J H Youn; N-H Cho
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

7.  Characterization of melanocyte-specific inducible Cre recombinase transgenic mice.

Authors:  Marcus Bosenberg; Viswanathan Muthusamy; David P Curley; Zhenxiong Wang; Cara Hobbs; Betsy Nelson; Cristina Nogueira; James W Horner; Ronald Depinho; Lynda Chin
Journal:  Genesis       Date:  2006-05       Impact factor: 2.487

8.  A phase 2 trial of dasatinib in advanced melanoma.

Authors:  Harriet M Kluger; Arkadiuz Z Dudek; Carrie McCann; Jean Ritacco; Nadine Southard; Lucia B Jilaveanu; Annette Molinaro; Mario Sznol
Journal:  Cancer       Date:  2010-11-29       Impact factor: 6.860

Review 9.  LKB1-dependent signaling pathways.

Authors:  Dario R Alessi; Kei Sakamoto; Jose R Bayascas
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

10.  Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

Authors:  Yasuyuki Deguchi; Shinya Kimura; Eishi Ashihara; Tomoko Niwa; Keiko Hodohara; Yoshihide Fujiyama; Taira Maekawa
Journal:  Leuk Res       Date:  2008-01-08       Impact factor: 3.156

View more
  68 in total

1.  Silencing of CD24 Enhances the PRIMA-1-Induced Restoration of Mutant p53 in Prostate Cancer Cells.

Authors:  Wei Zhang; Bin Yi; Chao Wang; Dongquan Chen; Sejong Bae; Shi Wei; Rong-Jun Guo; Changming Lu; Lisa L H Nguyen; Wei-Hsiung Yang; James W Lillard; Xingyi Zhang; Lizhong Wang; Runhua Liu
Journal:  Clin Cancer Res       Date:  2015-12-28       Impact factor: 12.531

2.  Tumor mutational burden as predictive factor of response to immunotherapy.

Authors:  Maria Gonzalez-Cao; Santiago Viteri; Niki Karachaliou; Andres Aguilar; Juan Jose García-Mosquera; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2018-12

3.  LKB1-AMPK axis revisited.

Authors:  Filippos Kottakis; Nabeel Bardeesy
Journal:  Cell Res       Date:  2012-07-17       Impact factor: 25.617

4.  Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.

Authors:  Christin E Burd; Wenjin Liu; Minh V Huynh; Meriam A Waqas; James E Gillahan; Kelly S Clark; Kailing Fu; Brit L Martin; William R Jeck; George P Souroullas; David B Darr; Daniel C Zedek; Michael J Miley; Bruce C Baguley; Sharon L Campbell; Norman E Sharpless
Journal:  Cancer Discov       Date:  2014-09-24       Impact factor: 39.397

5.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

6.  Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

Authors:  Yan Liu; Yuyang Li; Xiaoen Wang; Feiyang Liu; Peng Gao; Max M Quinn; Fei Li; Ashley A Merlino; Cyril Benes; Qingsong Liu; Nathanael S Gray; Kwok-Kin Wong
Journal:  Cancer Res       Date:  2017-07-28       Impact factor: 12.701

7.  Lkb1 deletion in murine B lymphocytes promotes cell death and cancer.

Authors:  George P Souroullas; Yuri Fedoriw; Louis M Staudt; Norman E Sharpless
Journal:  Exp Hematol       Date:  2017-04-21       Impact factor: 3.084

8.  Mesenchymal chemotaxis requires selective inactivation of myosin II at the leading edge via a noncanonical PLCγ/PKCα pathway.

Authors:  Sreeja B Asokan; Heath E Johnson; Anisur Rahman; Samantha J King; Jeremy D Rotty; Irina P Lebedeva; Jason M Haugh; James E Bear
Journal:  Dev Cell       Date:  2014-12-04       Impact factor: 12.270

9.  Serine/threonine kinase 32C is overexpressed in bladder cancer and contributes to tumor progression.

Authors:  Erlin Sun; Kangkang Liu; Kun Zhao; Lining Wang
Journal:  Cancer Biol Ther       Date:  2018-10-25       Impact factor: 4.742

10.  Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer.

Authors:  Yan Liu; Kevin Marks; Glenn S Cowley; Julian Carretero; Qingsong Liu; Thomas J F Nieland; Chunxiao Xu; Travis J Cohoon; Peng Gao; Yong Zhang; Zhao Chen; Abigail B Altabef; Jeremy H Tchaicha; Xiaoxu Wang; Sung Choe; Edward M Driggers; Jianming Zhang; Sean T Bailey; Norman E Sharpless; D Neil Hayes; Nirali M Patel; Pasi A Janne; Nabeel Bardeesy; Jeffrey A Engelman; Brendan D Manning; Reuben J Shaw; John M Asara; Ralph Scully; Alec Kimmelman; Lauren A Byers; Don L Gibbons; Ignacio I Wistuba; John V Heymach; David J Kwiatkowski; William Y Kim; Andrew L Kung; Nathanael S Gray; David E Root; Lewis C Cantley; Kwok-Kin Wong
Journal:  Cancer Discov       Date:  2013-05-28       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.